The UK is putting £20 million into four long-term centres intended to improve how emerging healthcare technologies are evaluated, reflecting a growing need for regulatory methods capable of keeping pace with software, AI, personalised medicine, and new treatment platforms.

The programme brings together the Medicines and Healthcare products Regulatory Agency, Medical Research Council, and Office for Life Sciences. Applications opened on 22 September and close on 12 January 2027.

Four Centres of Excellence for Regulatory Science and Innovation are expected to receive support, each concentrating on one of four themes: data-driven approaches and artificial intelligence; prevention, early detection and novel evidence; personalised healthcare and pharmacogenomics; and novel platform technologies.

The total fund can support programmes for up to five years, although awards will begin with three-year commitments and the final two years remain dependent on future spending decisions and budget allocation.

New technologies create new evidence problems

Healthcare regulation has traditionally been built around products whose characteristics can be defined comparatively clearly. AI software, personalised treatments, adaptive platforms, and data-driven diagnostics complicate that model because their performance can depend on datasets, software updates, and clinical workflows rather than a fixed physical product alone.

An AI-based medical device may require scrutiny of training data, performance across patient groups, software changes, drift, and behaviour after deployment as well as headline accuracy. Personalised medicine raises different questions around evidence generated from smaller or genetically defined populations.

The CERSI programme is intended to research those underlying methods rather than finance product development. Applicants must address regulatory science questions and show how their work could feed into policy, guidance, methodologies, tools, or regulatory decisions.

The programme follows shorter pilots

The UK established seven pilot CERSIs in 2025 with seed funding covering areas including AI and digital health, advanced therapies, medicines manufacturing, diagnostics, and pharmacogenomics. The new programme extends that model into longer research programmes.

Continuity can matter commercially as well as scientifically. Companies developing technologies that do not fit comfortably inside established regulatory categories face additional risk when evidence expectations remain uncertain.

Better regulatory science does not necessarily mean lighter or faster regulation in every case. New methods may reveal additional evidence requirements or expose shortcomings that older processes missed. The economic benefit comes from making requirements more scientifically appropriate and predictable before developers reach the end of expensive programmes.

Regulatory capacity becomes industrial infrastructure

The UK increasingly treats regulatory capability as part of its life-sciences strategy because predictable evaluation can influence where companies run studies, build teams, and introduce products.

Rules alone are not enough. Expertise in AI, genomics, data science, advanced therapies, and novel manufacturing is expensive, while regulators compete with universities and industry for many of the same specialists.

Research centres can extend that expertise beyond the regulator itself if their methods become part of routine practice rather than remaining in academic publications. The programme therefore requires sustained multidisciplinary work and routes into regulatory policy and decision-making.

Successful applicants are expected to emerge after the assessment process in early 2027. Their long-term value will be measured less by how many innovations they promote than by whether they give regulators defensible ways to evaluate technologies whose behaviour no longer fits comfortably inside older approval models.